Selected Highlights from the XIV International HIV Drug Resistance Workshop: Basic Principles and Clinical Implications

This annual workshop brings together leading laboratory and clinical scientists to present their latest research on HIV drug resistance and HIV drug resistance testing, which often results in innovative approaches to antiretroviral therapy. The Workshop is renowned for the quality of the data presented and the depth of the scientific interaction and debate.

This year the Workshop was held at the Fairmont Le Château Frontenac in Québec City, Québec, Canada on June 7-11, 2005. The Workshop continues to attract the most prominent scientists and clinicians, thereby, maintaining its reputation for cutting-edge science and service. Additionally, through support of our Funding Partners, scholarships are available for young scientists and community representatives.

The XIV International HIV Drug Resistance Workshop was held this year June 7-11, 2005 in Quebec City, Quebec, Canada. During the next week, each edition of HIV and Hepatitis.com will feature 3-4 summaries of data presentations from the Workshop, beginning today with the following abstracts:

Determination of Phenotypic Clinical Cutoffs for Atazanavir and Atazanavir/Ritonavir

Reduced Susceptibility to Protease Inhibitors (PI) in the Absence of Primary PI Resistance-Associated Mutations

Differences in Enhanced Susceptibilities to NNRTIs and to Zidovudine (ZDV) in Site Directed Mutants (SDMs) Bearing K65R, L74V or M184V

06/15/05

Source
XIV International HIV Drug Resistance Workshop. June 7-11, 2005. Quebec City, Quebec, Canada.

Return to Conference Main Page